SCHEMBL2972024

SCHEMBL2972024

CNN(C(=O)O)C(CC=O)C1CCN(Cc2cc(-c3ccc(Cl)cc3)no2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.42
DRD4 P21917 2/20 0.42
DRD3 P35462 2/20 0.42
LMNA P02545 1/20 0.41
F10 P00742 1/20 0.41
POLB P06746 1/20 0.41
HDAC3 O15379 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC7 Q8WUI4 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC10 Q969S8 1/20 0.41
HDAC11 Q96DB2 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HDAC9 Q9UKV0 1/20 0.41
HDAC5 Q9UQL6 1/20 0.41
USP30 Q70CQ3 4/20 0.40
HTT P42858 2/20 0.39
JAK2 O60674 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2981410 0.94 LMNA (0.40) DRD2DRD4DRD3LMNAF10
SCHEMBL2976754 0.90 LMNA (0.39) DRD2DRD4DRD3LMNAF10
SCHEMBL2970171 0.83 TEAD1 (0.45) HDAC1HDAC8HDAC6
Hydrochloric Acid SCHEMBL2971262 0.82 TEAD1 (0.44) HDAC1HDAC8HDAC6
SCHEMBL2965452 0.81 NPC1 (0.37) DRD2DRD4DRD3F10POLB
SCHEMBL2967614 0.80 NOTUM (0.38) LMNAHDAC3HDAC4HDAC1HDAC7
SCHEMBL2981437 0.80 MAPT (0.39) DRD2DRD4DRD3LMNAF10
SCHEMBL2982166 0.78 MCHR1 (0.45) POLBHDAC1KCNH2MCHR1
SCHEMBL3606182 0.76 DRD2 (0.51) DRD2DRD4DRD3LMNAF10
SCHEMBL2970365 0.76 BCHE (0.45) LMNAHTTALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7781590-B2 Piperidinylalkylcarbamate derivatives, methods for their preparation and the therapeutic use thereof as fatty acid amido hydrolase enzyme inhibitors SANOFI-AVENTIS (FR) 2010-08-24 US disclosed
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS SANOFI-AVENTIS (FR) 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021403-A1 PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS FAAH, FAAH2, CNR2 DRD2 1610/4885DRD4 1900/4885DRD3 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.